Drug class · Oncology & immunology
Kinase inhibitors Drug Codes & NDCs
Small-molecule drugs that inhibit one or more protein kinases. Most are oral products dispensed by pharmacies.
FDA-listed products
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Verzenioabemaciclib | Abemaciclib 100 mg/1 | TabletOral | Eli Lilly and Company | 0002-4815 |
| Verzenioabemaciclib | Abemaciclib 150 mg/1 | TabletOral | Eli Lilly and Company | 0002-5337 |
| Verzenioabemaciclib | Abemaciclib 200 mg/1 | TabletOral | Eli Lilly and Company | 0002-6216 |
| Vitrakvilarotrectinib | Larotrectinib 25 mg/1 | CapsuleOral | Bayer HealthCare Pharmaceuticals Inc. | 50419-390 |
| Vitrakvilarotrectinib | Larotrectinib 100 mg/1 | CapsuleOral | Bayer HealthCare Pharmaceuticals Inc. | 50419-391 |
| Vitrakvilarotrectinib | Larotrectinib 20 mg/mL | Solution, ConcentrateOropharyngeal | Bayer HealthCare Pharmaceuticals Inc. | 50419-392 |
| Vitrakvilarotrectinib | Larotrectinib 20 mg/mL | Solution, ConcentrateOropharyngeal | Bayer HealthCare Pharmaceuticals Inc. | 50419-393 |
| Vitrakvilarotrectinib | Larotrectinib 25 mg/1 | CapsuleOral | Loxo Oncology, Inc. | 71777-390 |
| Vitrakvilarotrectinib | Larotrectinib 100 mg/1 | CapsuleOral | Loxo Oncology, Inc. | 71777-391 |
| Vitrakvilarotrectinib | Larotrectinib 20 mg/mL | SolutionOral | Loxo Oncology, Inc. | 71777-392 |
| Vonjopacritinib | Pacritinib 100 mg/1 | CapsuleOral | Sobi, Inc. | 72482-100 |
| Votrientpazopanib hydrochloride | Pazopanib hydrochloride 200 mg/1 | Tablet, Film coatedOral | Novartis Pharmaceuticals Corporation | 0078-1077 |
| Xalkoricrizotinib | Crizotinib 20 mg/1 | Capsule, Coated pelletsOral | Pfizer Laboratories Div Pfizer Inc | 0069-0251 |
| Xalkoricrizotinib | Crizotinib 50 mg/1 | Capsule, Coated pelletsOral | Pfizer Laboratories Div Pfizer Inc | 0069-0507 |
| Xalkoricrizotinib | Crizotinib 150 mg/1 | Capsule, Coated pelletsOral | Pfizer Laboratories Div Pfizer Inc | 0069-1500 |
| Xalkoricrizotinib | Crizotinib 250 mg/1 | CapsuleOral | Pfizer Laboratories Div Pfizer Inc | 0069-8140 |
| Xalkoricrizotinib | Crizotinib 200 mg/1 | CapsuleOral | Pfizer Laboratories Div Pfizer Inc | 0069-8141 |
| Xeljanztofacitinib | Tofacitinib citrate 5 mg/1 | Tablet, Film coatedOral | Pfizer Laboratories Div Pfizer Inc | 0069-1001 |
| Xeljanztofacitinib | Tofacitinib citrate 10 mg/1 | Tablet, Film coatedOral | Pfizer Laboratories Div Pfizer Inc | 0069-1002 |
| Xeljanztofacitinib | Tofacitinib citrate 1 mg/mL | SolutionOral | Pfizer Laboratories Div Pfizer Inc | 0069-1029 |
| Xeljanztofacitinib | Tofacitinib citrate 5 mg/1 | Tablet, Film coatedOral | U.S. Pharmaceuticals | 63539-012 |
| Xeljanztofacitinib | Tofacitinib citrate 10 mg/1 | Tablet, Film coatedOral | U.S. Pharmaceuticals | 63539-016 |
| Xeljanztofacitinib | Tofacitinib citrate 1 mg/mL | SolutionOral | U.S. Pharmaceuticals | 63539-029 |
| Xeljanz XRtofacitinib | Tofacitinib citrate 11 mg/1 | Tablet, Film coated, Extended releaseOral | Pfizer Laboratories Div Pfizer Inc | 0069-0501 |
| Xeljanz XRtofacitinib | Tofacitinib citrate 22 mg/1 | Tablet, Film coated, Extended releaseOral | Pfizer Laboratories Div Pfizer Inc | 0069-0502 |